Baker Heart and Diabetes Institute (External organisation)

Description

The treatment or prophylaxis of organ and tissue fibrosis via modulation of cell division autoantigen (cda1)

Abstract: The present invention relates generally to the field of tissue fibrosis. More particularly, the present invention contemplates the treatment and prophylaxis of disease- or trauma- mediated organopathy which leads to tissue fibrosis. Even more particularly, the present invention is directed to the treatment and prophylaxis of diabetes, cardiovascular disease, Hepatitis infection and scar prevention following physical injury. This is achieved through modulation of the interaction between cell division autoantigen-1 (CDAl) and CDAl binding protein (CDAlBPl). The present invention enables clinical management of tissue fibrotic complications such as renal fibrosis, atherosclerosis, hepatic fibrosis and scaring.

WO2010083573A1 - WIPO (PCT)

Period	29 Jul 2010
Held at	Baker Heart and Diabetes Institute, Australia, Victoria
Degree of Recognition	International